Why has Patient Compliance become Important?

References

• Patient Compliance, L Lasagna. Futura, Mount Kisco, NY 1976
   Google Scholar
• Compliance with therapeutic regimens, D L Sackett, R B Haynes. Johns Hopkins University Press, Baltimore 1976
   Google Scholar
• Compliance in Health Care, R B Haynes, D W Taylor, D L Sackett. John Hopkins University press, Baltimore 1979
   Google Scholar
• Feinstein A R, Wood H F, Epstein J A, Taranta A, Simpson R, Tursky E. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med 1959; 260: 697–702
   PubMed Web of Science ®Google Scholar
• Moulding T. Proposal for a time recording pill dispenser as a method for studying and supervising the self-administration of drugs. Am Rev Resp Dis 1962; 85: 754–7
   Web of Science ®Google Scholar
• Joyce C RB. Patient co-operation and the sensitivity of clinical trials. J Chron Dis 1962; 15: 1025–36
   PubMedGoogle Scholar
• Peck C C. Qualitative aspects of therapeutic decision making. Chap 25. Clinical Pharmacology—Basic Principles in therapeutics, K L Melmon, H F Morrelli. Macmillan, New York 1978; 1063–83
   Google Scholar
• Peck C C. Should we improve patient compliance with therapeutic regimens, and, if so, how. Controversies in therapeutics, L Lasagna. Saunders, Philadelphia 1980; 559–66
   Google Scholar
• Potter L S. Oral contraceptive compliance and its role in the effectiveness of the method. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 195–207
   Google Scholar
• Urquhart J. Patient compliance as an explanatory variable in four selected cardiovascular studies. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 301–22
   Google Scholar
• Physician's Desk Reference. Oradell, NJ 1994; 1704
   Google Scholar
• Guillebaud J. Any questions. Brit Med J 1993; 307: 617
   Google Scholar
• Urquhart J, Heilmann K. Risk Watch—the Odds of Life. Facts on File, New York 1984
   Google Scholar
• Kass M A, Meltzer D, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515–523
   PubMed Web of Science ®Google Scholar
• Kass M A, Gordon M, Meltzer D W. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy. Am J Ophthalmol 1986; 101: 524–530
   PubMed Web of Science ®Google Scholar
• Kass M A, Gordon M, Morley R E, Meltzer D W, Goldberg J J. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103: 188–193
   PubMed Web of Science ®Google Scholar
• Cramer J A, Scheyer R D, Mattson R H. Compliance declines between clinic visits. Arch Int Med 1990; 150: 1509–10
   PubMed Web of Science ®Google Scholar
• Feinstein A R. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377–8
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results: (I) Reduction in incidence of coronary heart disease; (II) the relationship of reduction in incidence or coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–374
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo M O, Frick H, Haapa K, Feinonen O P, Heinsalmi P, Helo P, Huttunen J K, Kaitaniemi P, Koskinen P, Mäenpää H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila E A. Lipid alternations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–51
   PubMed Web of Science ®Google Scholar
• Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 1991; 86(413)7–17, Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 86 (413): 7–17, 1991.
   Web of Science ®Google Scholar
• Zeger S L, Liang K-Y. Comment: dose-response estimands. J Am Stat Assoc 1991; 86(413)18–9
   Web of Science ®Google Scholar
• Meier P. Discussion. J Am Stat Assoc 1991; 86(413)19–22
   Google Scholar
• Rubin D. Comment: dose-response estimands. J Am Stat Assoc 1991; 86(413)22–4
   Web of Science ®Google Scholar
• Feinstein A R. Intent-to-treat policy for analyzing randomized trials: statistical distortions and neglected clinical challenges. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 359–370
   Google Scholar
• Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 265–281
   Google Scholar
• Hurley F L. Statistical approach to subgroup analyses: patient compliance data and clinical outcomes. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 243–250
   Google Scholar
• Sheiner L B. The intellectual health of clinical drug evaluation. Clin Pharmacol ther 1991; 50: 4–9
   PubMed Web of Science ®Google Scholar
• Goetghebeur E JT, Pocock S J. Statistical issues in allowing for noncompliance and withdrawal. Drug Information J 1993; 27: 837–45
   Google Scholar
• Horwitz R I, Horwitz S M. Adherence to treatment and health outcomes. Arch Int Med 1993; 153: 1863–8
   PubMed Web of Science ®Google Scholar
• Johnson B F, Whelton A, McMahon F G. Betaxolol vs atenolol in hypertension: a comparison of efficacy, duration of response, and effects of withdrawal. Am J Hypertension 1990; 3(5), Part II, 121 A, Abstract 1429
   Google Scholar
• Knipschild P, Leffers P, Feinstein A R. The qualification period. J Clin Epidemiol 1991; 44: 461–4
   PubMed Web of Science ®Google Scholar
• Probstfield J L. Clinical trial prerandomization compliance (adherence) screen. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 323–333
   Google Scholar
• Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 1991; 41: 27–35
   PubMed Web of Science ®Google Scholar
• Matsui D, Hermann C, Braudo M, Ito S, Olivieri N, Koren G. Clinical use of the Medication Event Monitoring System: A new window into pediatric compliance. Clin Pharmacol ther 1992; 52: 102–3
   PubMed Web of Science ®Google Scholar
• Matsuyama J R, Mason B J, Jue S G. Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts. Ann Pharmacother 1993; 27: 851–5
   PubMed Web of Science ®Google Scholar
• Lasagna L. Noncompliance data and clinical outcomes: impact on health care. Primary Cardiology Suppl 1992; 1: 36–9
   Google Scholar
• Kruse W, Koch-Gwinner P, Nikolaus T, Oster P, Shlierf G, Weber E. Measurement of drug compliance by continuous electronic monitoring: a pilot study in elderly patients discharged from hospital. J Am Geriatr Soc 1992; 40: 1151–5
   PubMed Web of Science ®Google Scholar
• NIH Symposium on chemical markers for patient compliance. Controlled Clin Trials 1984; 5: 459–567
   PubMedGoogle Scholar
• Mäenpää H, Manninen V, Heinonen O P. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. European Heart J 1987; 8(supplement I)39–43
   PubMedGoogle Scholar
• Feely M, Cooke J, Price D, Singleton S, Mehta A, Bradford L, Calvert R. Low-dose phenobarbitone as an indicator of compliance with drug therapy. Br J Clin Pharmacol 1987; 24: 77–83
   PubMed Web of Science ®Google Scholar
• Kumar S, Haigh J RM, Rhodes L E, Peaker S, Davies J A, Roberts B E, Feely M P. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thrombosis Haemostasis 1989; 62: 729–32
   PubMed Web of Science ®Google Scholar
• Penn N D, Speaker S, Griffiths A P, Feely M, Tindall H. Use of a pharmacological indicator to monitor compliance with thyroxine. Eur J Clin Pharmacol 1988; 35: 327–329
   PubMed Web of Science ®Google Scholar
• Pullar T, Peaker S, Martin M FR, Bird H A, Feely M P. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Brit J Rheumatol 1988; 27: 381–4
   PubMedGoogle Scholar
• Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets. Clin Pharmacol ther 1989; 46: 163–8
   PubMed Web of Science ®Google Scholar
• Pullar T, Birtwell A J, Wiles P G, Hay A, Feely M P. Use of a pharmacologic indicator to compare compliance with tablets prescribed once, twice, or three times daily. Clin Pharmacol ther 1988; 44: 540–5
   PubMed Web of Science ®Google Scholar
• Glover F. U.S. Patent. 4, 034,757, 1976
   Google Scholar
• Kass M A, Zimmerman T, Yablonski M, Becker B. Compliance to pilocarpine therapy. Invest Ophthalmol (ARVO abstracts supplement) 1977; 108, abstract 2
   Google Scholar
• Kass M A, Meltzer D, Gordon M. A miniature compliance monitor for ophthalmology. Arch Ophthalmol 1984; 102: 1550
   PubMed Web of Science ®Google Scholar
• Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Information Journal 1988; 22: 363–378
   Google Scholar
• Cramer J A, Mattson R H, Prevey M L, Scheyer R D, Ouellette V L. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–3277
   PubMed Web of Science ®Google Scholar
• Kruse W, Weber E. Dynamics of drug regimen compliance—its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5
   PubMed Web of Science ®Google Scholar
• Averbuch M, Weintraub M, Pollack D J. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990; 4: 199–204
   Google Scholar
• Eisen S A, Woodward R S, Miller D, Spitznagel E, Windham C A. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2: 298–305
   PubMed Web of Science ®Google Scholar
• Cheung R, Dickins J, Nicholson P W, Thomas A SC, Smith H H, Larson H E, Deshmukh A A, Dobbs R J, Dobbs S M. Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed recording device. Eur J Clin Pharmacol 1988; 35: 401–7
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Rand C, Nides M, Simmons M, Wise R, Coulson A H, Li V, Gong H, Jr. A nebulizer chronolog to monitor compliance with inhaler use. Am J Med 1991; 91(suppl 4A)33S–36S
   PubMed Web of Science ®Google Scholar
• Lasagna L. Pharmacometry in man: the state of the art. Dose-response Relationships in Clinical Pharmacology. Esteve Foundation Symposia, vol 3, L Lasagna, S Erill, C A Naranjo. Excerpta Medica, Amsterdam 1989; 1–7
   Google Scholar
• Bond W S, Hussar D A. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991; 48: 1978–88
   PubMedGoogle Scholar
• Kruse W. Patient compliance with drug treatment—new perspectives on an old problem. Clin Investig 1992; 70: 163–6
   PubMedGoogle Scholar
• Pullar T, Feely M. Problems of compliance with drug treatment: new solutions. Pharm J 1990; 245: 213–5
   Google Scholar
• Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol ther 1990; 48: 676–85
   PubMed Web of Science ®Google Scholar
• Guerrero D, Rudd P, Bryant-Kosling C, Middleton B F. Antihypertensive medication-taking. Investigation of a simple regimen. Am J Hypertension 1993; 6: 586–92
   PubMed Web of Science ®Google Scholar
• Rudd P, Byyny R L, Zachary V, LoVerdé M E, Titus C, Mitchell W D, Marshall G. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol ther 1989; 46: 169–76
   PubMed Web of Science ®Google Scholar
• Wood H F, Simpson R, Feinstein A R, Taranta A, Tursky E, Stollerman G. Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. I. Description of the investigative techniques and of the population studied. Ann Int Med 1964; 60(suppl 5)6–17
   PubMedGoogle Scholar
• Feinstein A R. Compliance bias and the interpretation of therapeutic trials. Compliance in Health Care, R B Haynes, D W Taylor, D L Sackett. Johns Hopkins University Press, Baltimore 1979; 309–33
   Google Scholar
• Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1992; 68(suppl 3)S49–59
   PubMed Web of Science ®Google Scholar
• Lasagna L, Hutt P B. Health care, research, and regulatory impact of noncompliance. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 393–403
   Google Scholar
• Urquhart J. Real-time compliance monitoring in clinical trials: methods, early results, prospects. Human Psychopharmacology, v. III, I Hindmarch, P Stonier. John Wiley, ChichesterUK 1990; 129–147
   Google Scholar
• Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038–41
   PubMed Web of Science ®Google Scholar
• Lee Y J, Ellenberg J H, Hirta D G, Nelson K B. Analysis of clinical trials by treatment actually received: is it really an option. Stat Med 1991; 10: 1595–1605
   PubMed Web of Science ®Google Scholar
• QUESTRAN (cholestyramine). Physicians' Desk Reference. Medical Economics, Oradell, NJ 1994; 642–3
   Google Scholar
• Psaty B M, Koepsell T D, Wagner E H, LoGerfo J P, Inui T S. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990; 263: 1653–7
   PubMed Web of Science ®Google Scholar
• Long-term use of beta blockers: the need for sustained compliance. WHO Drug Information 1990; 4(2)52–3, Anon.
   Google Scholar
• Rangno R E, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am Heart J 1982; 104: 473–8
   PubMed Web of Science ®Google Scholar
• Didlake R H, Dreyfus K, Kerman R H, Van Buren C T, Kahan B D. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplantation Proceedings 1988; 20(Suppl 3)63–69
   PubMed Web of Science ®Google Scholar
• Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D, Schweizer R. Noncompliance in organ transplant recipients. Transplantation Proceedings 1989; 21(1)833–834
   PubMed Web of Science ®Google Scholar
• Nevins Thomas, Dr. Department of Pediatrics, University of Minnesota School of Medicine. 1993, personal communication
   Google Scholar
• Kruse W, Dr. Krankenhaus Bethanien. University of Heidelberg. 1994, personal communication
   Google Scholar
• Waterhouse D M, Calzone K A, Mele C, Brenner D E. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncololgy 1993; 11: 1189–97
   PubMed Web of Science ®Google Scholar
• Bloom B R, Murray C JL. Tuberculosis: commentary on a reemergent killer. Science 1992; 257: 1055–64
   PubMed Web of Science ®Google Scholar
• Geletko S, Jones K, Fiore T, Carpenter C, Flanigan T, Skowron G, Hayer K. Electronic monitoring of medication compliance in AIDS patients: importance in the assessment of fluconazole prophylaxis in high-risk women. Program and Abstracts, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1992, Abstract 1084
   Google Scholar
• Drehobl M, Kelsen S, Sahn S, Schleupner C, Puopolo A. Efficacy, safety, and compliance of cefixime QD compared with cefuroxime axetil BID in the treatment of bronchitis. Poster presented at American Osteopathic Association annual meeting, New Orleans, November, 31991
   Google Scholar
• Wood H F, Feinstein A R, Taranta A, Epstein J A, Simpson R. Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. III. Comparative effectiveness of three prophylaxis regimens in preventing streptococcal infections and rheumatic recurrences. Ann Int Med 1964; 60(suppl 5)31–46
   Google Scholar
• Gerson A C. Increasing maternal adherence to the sickle cell medical regimen: an intervention to decrease infant morbidity. Nova University, Ft. Lauderdale, Florida July 31, 1992, Ph.D. Dissertation
   Google Scholar
• Gerson A C, Pegelow C H, Armstrong F D, Faust J. The efficacy of an intervention to increase maternal adherence to prophylactic penicillin. Poster presented at the 1992 annual meeting of the National Sickle Cell Disease Program, Nashville, TN, March, 14–181992
   Google Scholar
• Urquhart J. Time to take our medicines, seriously. Pharm. Weekbl. 1992; 127: 769–76, (Inaugural professorial lecture, University of Limburg, April 3, 1992.)
   Google Scholar
• Kessler D A. Communicating with the patients about their medications. New Engl J Med 1991; 325: 1650–2
   PubMed Web of Science ®Google Scholar
• Can Patient Education Really Work. Proceedings of an Open Conference. Sept, 231992. United States Pharmacopeia, Rockville, MD 1993
   Google Scholar
• Urquhart J (1993) Cost-benefit assessment of patient education. Plenary Lecture in: Can Patient Education Really Work. Proceedings of an Open Conference. Sept, 231992. United States Pharmacopeia, Rockville, MD
   Google Scholar
• Helping patients to make the best use of medicines. Drug therap Bull Jan 7, 1991; 39(1), Anon.
   Google Scholar
• Kessler D A. Address to the annual meeting of the Controlled Release Society. FD&C Reports 1993; 55(31)15, (August 2)
   Google Scholar
• Levy G. A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol ther 1993; 54: 242–4
   PubMed Web of Science ®Google Scholar